Physician profile
Sameer Avasarala
NPI 1255673604
$23,714.96
in general payments reported to CMS, 2019-2025
18 companies · $12K in 2025
The $12K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,766 · 2020: $27.71 · 2021: $316 · 2022: $1,100 · 2023: $991 · 2024: $6,242 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Education: $2,500 · Travel and Lodging: $1,309 · Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,658.95 |
| Education | $2,500.00 |
| Travel and Lodging | $1,309.11 |
| Food and Beverage | $1,036.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $8,923.40 | 2021-2025 | Monarch Platform |
| Medical Device Business Services, INC. | $6,141.32 | 2024 | Monarch Platform |
| Intuitive Surgical, INC. | $3,602.02 | 2021-2025 | |
| Covidien LP | $2,755.08 | 2019-2020 | |
| Pinnacle Biologics, INC | $600.00 | 2023 | Photofrin |
| Noah Medical Corporation | $408.02 | 2024-2025 | Galaxy |
| Pulmonx Corporation | $397.65 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Medtronic, INC. | $322.06 | 2021-2022 | |
| Ethicon Endo-Surgery INC. | $217.18 | 2022 | |
| Steris Corporation | $157.66 | 2023 | |
| Olympus America INC. | $44.93 | 2023 | Spiration Valve System |
| Amgen INC. | $34.73 | 2022 | |
| Olympus Corporation of The Americas | $25.76 | 2019 | |
| Harmony Biosciences LLC | $25.09 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.27 | 2023 | Tezspire |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $16.25 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.26 | 2022 | |
| Merck Sharp & Dohme LLC | $13.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Avasarala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.